Prolonged activity nicotine patch

• US 4,943,435 A
• Filed: 10/28/1988
• Issued: 07/24/1990
• Est. Priority Date: 10/05/1987
• Status: Expired due to Term

• Current Assignee: McNeil AB (Johnson & Johnson)
• Original Assignee: Pharmetrix Corporation
• Inventors: Huang, Carl, Baker, Richard W., Kochinke, Frank
• Primary Examiner(s): Epstein, Henry F.
• Assistant Examiner(s): Ryan, P. S.
• Application Number:
  US07/264,397
• Time in Patent Office: 634 Days
• Field of Search: 424/448, 424/449, 424/486, 128/156, 128/632, 131/335
• US Class Current: 424/448
• CPC Class Codes: A61K 31/465 Nicotine; Derivatives thereof
• CPC Class Codes: A61K 9/7053 obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• CPC Class Codes: A61K 9/7069 obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

A transdermal patch for delivering nicotine for prolonged periods of 12-24 hours. The patch includes a rate-controlling membrane or monolith to keep the nicotine flux within useful and safe limits. The patch is typically replaced once a day, and can be used for smoking cessation therapy or in other situations where systemic nicotine delivery is indicated.

Claims

1. A transdermal patch, comprising:

(a) A nicotine depot layer, having a skin-facing side and a skin-distal side, said depot layer containing a sufficient quantity of nicotine to maintain a useful flux of nicotine from said patch for a total time period of 12 hours or more;

(b) an occlusive backing layer in contact with and covering said depot layer on said skin-distal side; and

(c) rate-controlling means for controlling diffusion of nicotine from said skin-facing side at a first flux of greater than zero but less than 2 mg/cm² in any hour for a first time period of greater than zero but less than 5 hours, then at a second flux between 20 and 800 μ

g/cm².h for a second time period of 7 hours or more.

2. The patch of claim 1, wherein said rate-controlling means comprises a nicotine-permeable polymer membrane contacting said depot layer on said skin-facing surface.

3. The patch of claim 1, wherein said rate-controlling means comprises a nicotine-permeable polymer monolith integral with said depot layer.

4. The patch of claim 1, wherein said rate-controlling means comprises a combination of a nicotine-permeable polymer monolith integral with said depot layer and a nicotine-permeable polymer membrane contacting said depot layer on said skin-facing surface.

5. The patch of claim 1, wherein said depot layer comprises a porous material with said nicotine dispersed therein.

6. The patch of claim 2, wherein said membrane is made from polyethylene.

7. The patch of claim 3, wherein said monolith is made from polyurethane.

8. The patch of claim 4, wherein said membrane is double-sided medical adhesive tape.

9. The patch of claim 1, wherein said first flux is greater than zero but less than 1 mg/cm² in any hour.

10. The patch of claim 1, wherein said first time period is less than 1 hour, and said second time period is 11 hours or more.

17. The method of claim 1, wherein said membrane is made from polyethylene.

11. A transdermal patch, comprising:

(a) a nicotine depot layer, having a skin-facing side and a skin-distal side, said depot layer containing a sufficient quantity of nicotine to maintain a useful flux of nicotine from said patch for a period of 12 hours or more;

(b) an occlusive backing layer in contact with and covering said depot layer on said skin-distal side; and

(c) rate-controlling means for controlling diffusion of nicotine from said skin-facing side at a flux between 20 and 800 μ

g/cm².h for a period of 12 hours or more.

12. A method of administering nicotine to an individual in need of such administration, comprising applying to the skin of said individual a transdermal patch, said patch comprising:

(a) a nicotine depot layer, having a skin-facing side and a skin-distal side, said depot layer containing a sufficient quantity of nicotine to maintain a useful flux of nicotine from said patch for a total time period of 12 hours or more;

(b) an occlusive backing layer in contact with and covering said depot layer on said skin-distal side; and

(c) rate-controlling means for controlling diffusion of nicotine from said skin-facing side at a first flux less 2 mg/cm².h for a first time period less than 5 hours, then at a second flux between 20 and 800 μ

g/cm².h for a second time period of 7 hours or more.

13. The method of claim 12, wherein said rate-controlling means comprises a nicotine-permeable polymer membrane contacting said depot layer on said skin-facing surface.

14. The method of claim 12, wherein said rate-controlling means comprises a nicotine-permeable polymer monolith integral with said depot layer.

15. The method of claim 12, wherein said rate-controlling means comprises a combination of a nicotine-permeable polymer monolith integral with said depot layer and a nicotine-permeable polymer membrane contacting said depot layer on said skin-facing surface.

16. The method of claim 12, wherein said depot layer comprises a porous material with said nicotine dispersed therein.

18. The method of claim 14, wherein said monolith is made from polyurethane.

19. The method of claim 15, wherein said membrane is double-sided medical adhesive tape.

20. The method of claim 12, wherein said first flux is less than 1 mg/cm².h.

21. The method of claim 12, wherein said first time period is less than 1 hour, and said second time period is 11 hours or more.

22. A method of administering nicotine to an individual in need of such administration, comprising applying to the skin of said individual a transdermal patch, said patch comprising:

(a) a nicotine depot layer, having a skin-facing side and a skin-distal side, said depot layer containing a sufficient quantity of nicotine to maintain a useful flux of nicotine from said patch for a period of 12 hours or more;

(b) an occlusive backing layer in contact with and covering said depot layer on said skin-distal side; and

(c) rate-controlling means for controlling diffusion of nicotine from said skin-facing side at a flux between 20 and 800 μ

g/cm².h for a period of 12 hours or more.